There were no T cell-jolting developments, but new ground was broken at the prestigious eighth-annual Conference on Retroviruses and Opportunistic Infections in Chicago in February. Tongues were wagging about antiretrovirals -- good results with new classes, including fusion inhibitors and chemokine attackers, and with side-effect reduction -- a new Bristol Myers protease inhibitor (BMS-232632) is potent but doesn’t raise blood fats. POZ will keep you posted, as these advances develop (or not) into solutions for lipodystrophy and drug resistance. Meanwhile, eyeball the hot type below.